Arvinas, Inc. (NASDAQ:ARVN) Insider Sells $74,372.22 in Stock

Arvinas, Inc. (NASDAQ:ARVN) insider Noah Berkowitz sold 8,658 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total transaction of $74,372.22. Following the transaction, the insider now owns 110,023 shares in the company, valued at $945,097.57. The trade was a 7.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Arvinas Stock Down 2.8 %

Shares of NASDAQ ARVN opened at $8.75 on Friday. The company’s fifty day moving average is $16.24 and its 200-day moving average is $21.29. The stock has a market cap of $601.76 million, a price-to-earnings ratio of -3.16 and a beta of 1.95. Arvinas, Inc. has a twelve month low of $7.91 and a twelve month high of $43.07.

Arvinas (NASDAQ:ARVN) last posted its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter last year, the firm earned ($2.53) EPS. On average, research analysts anticipate that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. BTIG Research assumed coverage on Arvinas in a report on Tuesday, December 10th. They set a “buy” rating and a $69.00 price objective on the stock. The Goldman Sachs Group lowered Arvinas from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $70.00 to $15.00 in a research report on Thursday, March 13th. Wells Fargo & Company set a $26.00 price target on Arvinas and gave the company an “overweight” rating in a report on Wednesday, March 12th. Citigroup decreased their price target on Arvinas from $28.00 to $19.00 and set a “neutral” rating on the stock in a report on Friday, March 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $81.00 target price on shares of Arvinas in a research note on Tuesday, March 11th. Five analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, Arvinas presently has a consensus rating of “Moderate Buy” and an average price target of $37.47.

Hedge Funds Weigh In On Arvinas

Several institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new position in Arvinas in the fourth quarter valued at approximately $28,000. KBC Group NV lifted its position in Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after acquiring an additional 1,255 shares in the last quarter. Quantbot Technologies LP lifted its position in Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after acquiring an additional 2,601 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in Arvinas in the 4th quarter valued at $171,000. Finally, Tema Etfs LLC bought a new stake in shares of Arvinas in the fourth quarter valued at about $227,000. Institutional investors own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.